ESR1 and breast cancer: In patients with ER+ breast cancer, 6 months of neoadjuvant treatment with letrozole +/− cyclophosphamide reduces P-AKTS473 and P-mTORS2448 tumor levels, which correlate with improved response and disease outcome [37].